Sabbin magunguna don ciwon motsi

A ranar 15 ga Mayu, Vanda Pharmaceuticals, wani kamfanin samar da magunguna na Amurka, ya ba da sanarwar cewa binciken kashi na biyu na biyu na sabon maganin Tradipitant (mai ciniki) don maganin cututtukan motsi (musamman cututtukan motsi) ya sami sakamako mai kyau.
Tradipitant ne neurokinin-1 (NK1) antagonist mai karɓa wanda Eli Lilly ya haɓaka. Vanda ya sami haƙƙin ci gaban duniya na Tradipitant ta hanyar lasisi a cikin Afrilu 2012.
A halin yanzu, Vanda ya haɓaka Tradipitant don alamu kamar atopic dermatitis pruritus, gastroparesis, sabon kamuwa da cuta na coronavirus, cututtukan motsi, buri na barasa, phobia na zamantakewa, da rashin narkewar abinci.
Wannan binciken na 3 na Phase ya haɗa da marasa lafiya na motsi na 316 tare da tarihin ciwon motsi, waɗanda aka bi da su tare da 170 MG Tradipitant, 85 MG Tradipitant, ko placebo a lokacin tafiya na jirgin ruwa.
Duk mahalarta binciken suna da tarihin ciwon teku. Babban mahimmancin binciken shine tasirin tradipitant (170 MG) akan amai. Mabuɗin ƙarshen ƙarshen biyu sune: (1) tasirin tradipitant (85 MG) akan amai; (2) tasirin tradipitant wajen hana tsananin tashin zuciya da amai.
An ba da rahoton cewa ciwon motsi ya kasance buƙatun likita da ba a biya ba. Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da sabon magani don maganin cututtukan motsi ba fiye da shekaru 40 tun lokacin da ta amince da scopolamine (wani facin transdermal da aka sanya a bayan kunne) a cikin 1979.

Dangane da bayanan daga karatun Mataki na III na biyu, Vanda zai gabatar da aikace-aikacen talla don masu cin kasuwa ga FDA don kula da cututtukan motsi a cikin kwata na huɗu na 2024.